181 related articles for article (PubMed ID: 7051722)
1. Propranolol does not inhibit sulphonylurea-stimulated insulin secretion in patients with non-insulin dependent diabetes mellitus.
Groop L; Tötterman KJ
Acta Endocrinol (Copenh); 1982 Jul; 100(3):410-5. PubMed ID: 7051722
[TBL] [Abstract][Full Text] [Related]
2. No effect of propranolol and metoprolol on tolbutamide-stimulated insulin-secretion in hypertensive diabetic and non-diabetic patients.
Tötterman KJ; Groop LC
Ann Clin Res; 1982 Aug; 14(4):190-3. PubMed ID: 6762846
[TBL] [Abstract][Full Text] [Related]
3. Glipizide versus tolbutamide, an open trial. Effects on insulin secretory patterns and glucose concentrations.
Fineberg SE; Schneider SH
Diabetologia; 1980 Jan; 18(1):49-54. PubMed ID: 6988265
[TBL] [Abstract][Full Text] [Related]
4. Lack of primary effect of sulphonylurea (glipizide) on plasma lipoproteins and insulin action in former type 2 diabetics with attenuated insulin secretion.
Sartor G; Ursing D; Nilsson-Ehle P; Wåhlin-Boll E; Melander A
Eur J Clin Pharmacol; 1987; 33(3):279-82. PubMed ID: 3319648
[TBL] [Abstract][Full Text] [Related]
5. Extrapancreatic effects of a sulphonylurea. Decrease in xylose absorption by glipizide in type II diabetics.
Kollind M; Adamson U; Lins PE; Ohlsén P
Acta Med Scand; 1984; 215(5):443-5. PubMed ID: 6377829
[TBL] [Abstract][Full Text] [Related]
6. [The influence of various sulphonylurea derivatives on the oral glucose-tolerance tests in healthy subjects and obese and maturity-onset diabetics (author's transl)].
Haupt E; Beyer J; Schöffling K
Dtsch Med Wochenschr; 1974 Mar; 99(9):385-8. PubMed ID: 4208186
[No Abstract] [Full Text] [Related]
7. Effects of glipizide on various consecutive insulin secretory stimulations in patients with type 2 diabetes.
Ahrén B; Lundquist I; Scherstén B
Diabetes Res; 1986 Jul; 3(6):293-300. PubMed ID: 3530592
[TBL] [Abstract][Full Text] [Related]
8. [Changes in insulin (IRI) and NEFA levels in diabetic subjects after acute intravenous glipizide and tolbutamide administration].
Fedeli S; Maglia A
Arch Sci Med (Torino); 1977; 134(1):33-8. PubMed ID: 860916
[TBL] [Abstract][Full Text] [Related]
9. Effect of glipizide on insulin secretion and insulin metabolism in obese type II diabetic patients.
Bonora E; Pisani F; Micciolo R; Corgnati A; Muggeo M
Diabetes Care; 1987; 10(6):687-91. PubMed ID: 3322723
[TBL] [Abstract][Full Text] [Related]
10. Diazoxide, glipizide, and hypoglycaemia.
Greenwood RH; Mahler RF; Hales CN
Lancet; 1977 Feb; 1(8006):307-8. PubMed ID: 64831
[No Abstract] [Full Text] [Related]
11. Therapeutic effect of tolbutamide in non-insulin dependent diabetes mellitus (NIDDM). Relation to beta-cell function.
Damsgaard EM; Faber O; Frøland A; Iversen S
Acta Endocrinol (Copenh); 1982 Jul; 100(3):416-20. PubMed ID: 7051723
[TBL] [Abstract][Full Text] [Related]
12. Glipizide increases plasma insulin but not C-peptide level after a standardized breakfast in type 2 diabetic patients.
Scheen AJ; Lefebvre PJ; Luyckx AS
Eur J Clin Pharmacol; 1984; 26(4):471-4. PubMed ID: 6376145
[TBL] [Abstract][Full Text] [Related]
13. Insulin in portal, hepatic and peripheral venous blood after glucose, tolbutamide and glipizide stimulation. Indication of insulin release from peripheral tissues.
Hed R; Nygren A; Röjdmark R; Sundblad L; Wiechel KL
Acta Med Scand; 1979; 205(3):221-5. PubMed ID: 371340
[TBL] [Abstract][Full Text] [Related]
14. Effect of sulphonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: a dose-response study.
Groop LC; Ratheiser K; Luzi L; Melander A; Simonson DC; Petrides A; Bonadonna RC; Widén E; DeFronzo RA
Acta Diabetol; 1991; 28(2):162-8. PubMed ID: 1777653
[TBL] [Abstract][Full Text] [Related]
15. Effects of sulfonylurea on the secretion and disposition of insulin and C-peptide.
Almér LO; Johansson E; Melander A; Wåhlin-Boll E
Acta Med Scand Suppl; 1981; 656():11-8. PubMed ID: 7046346
[TBL] [Abstract][Full Text] [Related]
16. Influence of sulfonylureas on the secretion, disposal and effect of insulin.
Almér LO; Johansson E; Melander A; Wåhlin-Boll E
Eur J Clin Pharmacol; 1982; 22(1):27-32. PubMed ID: 7047169
[TBL] [Abstract][Full Text] [Related]
17. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
Carroll MF; Izard A; Riboni K; Burge MR; Schade DS
Diabetes Care; 2002 Dec; 25(12):2147-52. PubMed ID: 12453952
[TBL] [Abstract][Full Text] [Related]
18. A study of the possible interaction of indoprofen with hypoglycemic sulfonylureas in diabetic patients.
Pedrazzi F; Bommartini F; Freddo J; Emanueli A
Eur J Rheumatol Inflamm; 1981; 4(1):26-31. PubMed ID: 7042358
[TBL] [Abstract][Full Text] [Related]
19. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
20. The acute effect of preprandial exogenous and endogenous sulphonylurea-stimulated insulin secretion on postprandial glucose excursions in patients with type 2 diabetes.
Groop PH; Melander A; Groop LC
Diabet Med; 1993; 10(7):633-7. PubMed ID: 8403824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
